FindTrial
Sign In

Prospective clinical trial on the diagnosis and minimally invasive therapy of massive hemoptysis caused by pulmonary arteriovenous malformations with bronchiectasis

Prospective clinical trial on the diagnosis and minimally invasive therapy of massive hemoptysis cau

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-14005326
Enrollment
Unknown
Registered
2014-10-12
Start date
2014-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Massive hemoptysis caused by pulmonary arteriovenous malformations with bronchiectasis

Interventions

1:minimally invasive therapy

Sponsors

The First Hospital, Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years old; 2.Massive hemoptysis unable to be controlled by Medicine; 3. Lesions in a wide range to surgical resection; 4. X-ray, MRI, CT, DSA confirmed pulmonary arteriovenous malformations with bronchiectasis; 5. Cardiopulmonary function without serious obstacle; 6. Normal liver and kidney function; 7. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Non- bronchiectasis; 2. Little hemoptysis or can be controlled by medicine; 3. Pulmonary congestion or severe congenital heart disease; 4. Blood glucose level less than 2.7mmol/L or more than 22.2mmol/L; 5. Estimated survival less than 1 year; 6. Severe emphysema, lung functions reduced seriously; 7.Allergic to contrast medium.

Design outcomes

Primary

MeasureTime frame
Survival rate;Symptom improvement;Adverse reaction;Therapeutic effect;Complication;Related factors of recurrence;Imageological examination;—

Contacts

Public ContactXinwei Han
hanxinwei2006@163.com+86 0 13803842129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026